Chengdu Kanghong Pharmaceutical Group Co., Ltd. engages in the research, development, production and sale of Chinese patent medicines, chemical medicines and biological products. Its products include Conbercept Ophthalmic Injection, Shugan Jieyu Jiaonang, Ganke Shuangqing Jiaonang, Yiqing Jiaonang, Venlafaxine Hydrochloride Capsules, Xuan Maigangu, Aripiprazole, Keluoxin, Danshu Jiaonang, Mosapride Citrate, and Dexzopiclone. The company was founded on October 3, 1996 and is headquartered in Chengdu, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company